Shares of Scancell Holdings plc (LON:SCLP – Get Free Report) were up 29.8% on Monday . The stock traded as high as GBX 11.38 ($0.15) and last traded at GBX 11 ($0.15). Approximately 10,537,342 shares changed hands during mid-day trading, an increase of 1,073% from the average daily volume of 897,982 shares. The stock had previously closed at GBX 8.48 ($0.11).
Scancell Stock Performance
The company has a market capitalization of £113.93 million, a price-to-earnings ratio of -16.86 and a beta of 0.35. The company’s fifty day simple moving average is GBX 8.47 and its two-hundred day simple moving average is GBX 10.86. The company has a debt-to-equity ratio of -566.79, a quick ratio of 13.01 and a current ratio of 3.42.
Scancell (LON:SCLP – Get Free Report) last announced its quarterly earnings data on Thursday, January 30th. The company reported GBX (1.35) (($0.02)) earnings per share (EPS) for the quarter. Equities research analysts predict that Scancell Holdings plc will post -2.5361112 earnings per share for the current fiscal year.
About Scancell
Scancell (LSE:SCLP) is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers.
Scancell has developed a pipeline of ‘off-the-shelf’ vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.
Featured Articles
- Five stocks we like better than Scancell
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- Why NVIDIA Stock Could Soar Despite Wall Street Downgrades
- ESG Stocks, What Investors Should Know
- Top 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or Hold
- What is a penny stock? A comprehensive guide
- 3 Hot New IPOs Defying the 2025 Market Slump
Receive News & Ratings for Scancell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scancell and related companies with MarketBeat.com's FREE daily email newsletter.